Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

NCT05292950 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT05292950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
June 27, 2022
Completion date
November 12, 2024
Enrollment
78 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic obstructive pulmonary disease